A recent study presented by ISPOR demonstrated how HEOR data positively influenced changes to US payer formulary coverage. Investigators surveyed the scientific literature and industry and payer policy to evaluate instances of HEOR datasets impacting US formulary coverage in a tangible way. For example, investigators found that HEOR data positively impacted formulary coverage in the case of tiotropium bromide’s pharmaco-economic model which linked its exacerbations data to downstream savings, resulting in some payers to prefer it in the COPD setting. The study authors conclude that understanding the ever-evolving payer interpretations of HEOR analyses may help reconcile the underlying rationale shaping value perceptions. Read more here.
(Source: Gould A et al., August 31, 2020)